Papers
Research literature with structured metadata.
Trials
Registered studies by status, phase, and compound.
Topics
Indications and themes psychedelics are researched for.
Compounds
Evidence across molecules with rich data.
Countries
Regulation, access, and research activity by region.
Stakeholders
Organizations shaping the space across research, policy, and funding.
People
Investigators, clinicians, and authors with mapped output.
Courses
Training programs and certifications across modalities.
Events
Conferences, workshops, and convenings by date and focus.
Research recaps
Monthly evidence summaries with key takeaways.
Map of research
Landscape view of trials, compounds, and outcomes.
Newsletter
Weekly or daily updates on trials, publications, analysis, and more.
Research Groups
Worldwide map of psychedelic research centres by region.
Research Network
Interactive co-authorship map of psychedelic researchers.
Top papers
Find needles in the haystack of psychedelic research per topic.
The paper analyses the ethical and legal risks therapists face when supporting clients who use prohibited psychedelics and argues that a harm‑reduction framework enables clinicians to mitigate those risks. It recommends pre‑ and post‑experience sessions and practical strategies so therapists can help clients minimise harms and maximise therapeutic benefit while striving to remain within legal and ethical boundaries.
Analysis of YouTube self‑reports and comments found that users predominantly describe therapeutic and enhancement benefits from psychedelic microdosing (mainly LSD and psilocybin), with notable improvements for depression and outcomes shaped by intentions and peer‑shared strategies. The study suggests microdosing may offer some benefits similar to full‑dose treatments with fewer acute adverse reactions, but repeated long‑term exposure could introduce additional risks.
This survey study (n=278) aimed to develop a codebook of benefits and challenges associated with microdosing. The authors found, among other things, that many parallels exist between the effects reported as benefits and those reported as challenges.
This qualitative study (2017) examined self-reports from online forums about psychoactive substance use for treating migraines and cluster headaches, and found that psychedelic tryptamines, primarily LSD and psilocybin, were frequently reported to lessen both their frequency and intensity of pain at sub-psychoactive doses.